In short
This article summarizes several clinical trials evaluating the safety, tolerability, and immunogenicity of recombinant Neisseria meningitidis group B vaccines, particularly focusing on the vaccine component containing recombinant factor H binding protein (fHbp) produced in E. coli cells and adsorbed on aluminum hydroxide. These trials are investigating the vaccine's use in various populations, including healthy adolescents, infants, adults with asplenia, and patients with certain medical conditions. The studies aim to assess immune responses, safety profiles, and optimal dosing schedules for protection against meningococcal disease caused by serogroup B strains.
At a glance
- Vaccine Components
- Recombinant Neisseria Meningitidis Group B fHbp, NadA, and NHBA fusion proteins, plus outer membrane vesicles (OMV)
- Primary Objectives
- Assess safety, tolerability, and immunogenicity of meningococcal B vaccines
- Study Populations
- Healthy adolescents, infants, adults with asplenia, patients with specific medical conditions
- Key Outcome Measures
- hSBA titers, seroconversion rates, adverse events, geometric mean titers
- Safety Assessments
- Monitoring of adverse events, injection site reactions, systemic events
- Immunogenicity Assessments
- Measurement of antibody responses using hSBA assays
- Study Designs
- Randomized, controlled, blinded or partially blinded, with varying dosing schedules
- Follow-up Periods
- Range from several months to multiple years for long-term assessment
What is the Meningococcal Group B Vaccine?
The meningococcal group B vaccine, also known as Bexsero, is a vaccine designed to prevent meningococcal disease caused by Neisseria meningitidis serogroup B bacteria. This vaccine contains several key components:
- Recombinant Neisseria meningitidis group B NHBA fusion protein
- Recombinant Neisseria meningitidis group B NadA protein
- Recombinant Neisseria meningitidis group B fHbp fusion protein
- Outer membrane vesicles (OMV) from Neisseria meningitidis group B
These components are produced using recombinant DNA technology in E. coli cells and are adsorbed on aluminum hydroxide to enhance the immune response.
How Does It Work?
The vaccine works by stimulating the body's immune system to produce antibodies against specific proteins found on the surface of meningococcal B bacteria. When a vaccinated person is exposed to these bacteria, their immune system can quickly recognize and fight off the infection, preventing the development of meningococcal disease.
Who Needs This Vaccine?
The meningococcal group B vaccine is recommended for several groups of people:
- Adolescents and young adults (ages 16-23) who are at increased risk of meningococcal disease
- People with certain medical conditions that increase their risk of meningococcal infections, such as asplenia (absence of a functioning spleen)
- Laboratory workers who are routinely exposed to Neisseria meningitidis
- People at risk during outbreaks of meningococcal B disease
Dosing and Administration
The vaccine is typically administered as an intramuscular injection. The dosing schedule can vary depending on the age and risk factors of the individual. For most people, a series of two or three doses is recommended:
- Two doses given at least 1 month apart
- In some cases, a third dose may be given 6 months after the second dose
It's important to follow the recommended schedule to ensure the best protection against meningococcal B disease.
Effectiveness
Clinical trials have shown that the meningococcal group B vaccine is effective in producing an immune response against various strains of Neisseria meningitidis serogroup B. One study found that after two doses, a high percentage of participants had protective antibody levels against multiple meningococcal B strains.
Safety and Side Effects
The meningococcal group B vaccine has been shown to have a good safety profile in clinical trials. However, like all vaccines, it can cause some side effects. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle or joint pain
- Nausea
- Fever
Most side effects are mild and resolve within a few days. Serious allergic reactions are rare but can occur. If you experience any severe symptoms after vaccination, seek medical attention immediately.
Use in Special Populations
Research is ongoing to evaluate the safety and effectiveness of the meningococcal group B vaccine in various populations. Some studies are focusing on:
- Adults with asplenia (absence of a functioning spleen): A study is assessing the immunogenicity and safety of different meningococcal B vaccine strategies in this population.
- Infants and young children: Studies are evaluating the use of the vaccine in combination with other routine childhood vaccinations.
- Older adults: Research is being conducted to assess the safety and effectiveness of the vaccine in adults over 65 years of age.
Ongoing Research
Several clinical trials are currently underway to further investigate the meningococcal group B vaccine:
- A study is examining different dosing schedules in healthy adolescents to optimize the vaccination strategy.
- Another trial is evaluating a combined vaccine that protects against meningococcal serogroups A, B, C, W, and Y in infants.
- Researchers are also studying the long-term persistence of antibodies and the potential need for booster doses.
These ongoing studies will help to refine vaccination strategies and ensure the best possible protection against meningococcal disease for various populations.